Logo image of TBPH

THERAVANCE BIOPHARMA INC (TBPH) Stock Fundamental Analysis

NASDAQ:TBPH - Nasdaq - KYG8807B1068 - Common Stock - Currency: USD

11.47  +0.17 (+1.5%)

After market: 11.47 0 (0%)

Fundamental Rating

3

Taking everything into account, TBPH scores 3 out of 10 in our fundamental rating. TBPH was compared to 193 industry peers in the Pharmaceuticals industry. TBPH scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. While showing a medium growth rate, TBPH is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

TBPH had negative earnings in the past year.
TBPH had a positive operating cash flow in the past year.
In the past 5 years TBPH reported 4 times negative net income.
In the past 5 years TBPH always reported negative operating cash flow.
TBPH Yearly Net Income VS EBIT VS OCF VS FCFTBPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M 600M 800M

1.2 Ratios

The Return On Assets of TBPH (-16.98%) is better than 62.69% of its industry peers.
With a Return On Equity value of -35.14%, TBPH perfoms like the industry average, outperforming 59.07% of the companies in the same industry.
Industry RankSector Rank
ROA -16.98%
ROE -35.14%
ROIC N/A
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TBPH Yearly ROA, ROE, ROICTBPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

TBPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TBPH Yearly Profit, Operating, Gross MarginsTBPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

More info and screens

6

2. Health

2.1 Basic Checks

TBPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for TBPH has been increased compared to 1 year ago.
Compared to 5 years ago, TBPH has less shares outstanding
The debt/assets ratio for TBPH is higher compared to a year ago.
TBPH Yearly Shares OutstandingTBPH Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
TBPH Yearly Total Debt VS Total AssetsTBPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of -1.89, we must say that TBPH is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of TBPH (-1.89) is comparable to the rest of the industry.
TBPH has a debt to FCF ratio of 0.96. This is a very positive value and a sign of high solvency as it would only need 0.96 years to pay back of all of its debts.
TBPH has a better Debt to FCF ratio (0.96) than 95.85% of its industry peers.
TBPH has a Debt/Equity ratio of 0.19. This is a healthy value indicating a solid balance between debt and equity.
TBPH has a Debt to Equity ratio of 0.19. This is comparable to the rest of the industry: TBPH outperforms 44.56% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.96
Altman-Z -1.89
ROIC/WACCN/A
WACC9.82%
TBPH Yearly LT Debt VS Equity VS FCFTBPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

TBPH has a Current Ratio of 4.77. This indicates that TBPH is financially healthy and has no problem in meeting its short term obligations.
TBPH has a better Current ratio (4.77) than 68.91% of its industry peers.
A Quick Ratio of 4.77 indicates that TBPH has no problem at all paying its short term obligations.
With a decent Quick ratio value of 4.77, TBPH is doing good in the industry, outperforming 70.47% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.77
Quick Ratio 4.77
TBPH Yearly Current Assets VS Current LiabilitesTBPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

4

3. Growth

3.1 Past

TBPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.23%.
Looking at the last year, TBPH shows a small growth in Revenue. The Revenue has grown by 6.18% in the last year.
TBPH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.59% yearly.
EPS 1Y (TTM)-30.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
Revenue 1Y (TTM)6.18%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%6.1%

3.2 Future

The Earnings Per Share is expected to grow by 36.17% on average over the next years. This is a very strong growth
Based on estimates for the next years, TBPH will show a very strong growth in Revenue. The Revenue will grow by 28.13% on average per year.
EPS Next Y135.84%
EPS Next 2Y24.79%
EPS Next 3Y27.11%
EPS Next 5Y36.17%
Revenue Next Year52.71%
Revenue Next 2Y22.83%
Revenue Next 3Y27.17%
Revenue Next 5Y28.13%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
TBPH Yearly Revenue VS EstimatesTBPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 100M 200M 300M
TBPH Yearly EPS VS EstimatesTBPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 5 -5 10

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for TBPH. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TBPH. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TBPH Price Earnings VS Forward Price EarningsTBPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20 30

4.2 Price Multiples

84.97% of the companies in the same industry are more expensive than TBPH, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 17.76
EV/EBITDA N/A
TBPH Per share dataTBPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

TBPH's earnings are expected to grow with 27.11% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y24.79%
EPS Next 3Y27.11%

More info and screens

0

5. Dividend

5.1 Amount

TBPH does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

THERAVANCE BIOPHARMA INC

NASDAQ:TBPH (7/14/2025, 8:07:16 PM)

After market: 11.47 0 (0%)

11.47

+0.17 (+1.5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-04 2025-08-04
Inst Owners91.82%
Inst Owner Change0%
Ins Owners4.79%
Ins Owner Change2.35%
Market Cap573.50M
Analysts80
Price Target17.34 (51.18%)
Short Float %8.74%
Short Ratio13.96
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-30.41%
Min EPS beat(2)-44.72%
Max EPS beat(2)-16.1%
EPS beat(4)0
Avg EPS beat(4)-26.03%
Min EPS beat(4)-44.72%
Max EPS beat(4)-10.35%
EPS beat(8)2
Avg EPS beat(8)-14.88%
EPS beat(12)3
Avg EPS beat(12)-28.11%
EPS beat(16)5
Avg EPS beat(16)-26.92%
Revenue beat(2)1
Avg Revenue beat(2)2.46%
Min Revenue beat(2)-2.67%
Max Revenue beat(2)7.58%
Revenue beat(4)2
Avg Revenue beat(4)0.79%
Min Revenue beat(4)-9.55%
Max Revenue beat(4)7.78%
Revenue beat(8)4
Avg Revenue beat(8)-0.96%
Revenue beat(12)5
Avg Revenue beat(12)-4.23%
Revenue beat(16)6
Avg Revenue beat(16)-5.07%
PT rev (1m)11.48%
PT rev (3m)17.24%
EPS NQ rev (1m)376.1%
EPS NQ rev (3m)373.58%
EPS NY rev (1m)214.67%
EPS NY rev (3m)214.67%
Revenue NQ rev (1m)62.28%
Revenue NQ rev (3m)61.7%
Revenue NY rev (1m)5.72%
Revenue NY rev (3m)0.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.79
P/FCF 17.76
P/OCF 17.63
P/B 3.46
P/tB 3.46
EV/EBITDA N/A
EPS(TTM)-1.12
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)0.65
FCFY5.63%
OCF(TTM)0.65
OCFY5.67%
SpS1.31
BVpS3.32
TBVpS3.32
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -16.98%
ROE -35.14%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM 49.47%
ROA(3y)37.73%
ROA(5y)0.15%
ROE(3y)46.45%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.19
Health
Industry RankSector Rank
Debt/Equity 0.19
Debt/FCF 0.96
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.77
Quick Ratio 4.77
Altman-Z -1.89
F-Score4
WACC9.82%
ROIC/WACCN/A
Cap/Depr(3y)20.39%
Cap/Depr(5y)43.25%
Cap/Sales(3y)1.99%
Cap/Sales(5y)4.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-30.23%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-12.5%
EPS Next Y135.84%
EPS Next 2Y24.79%
EPS Next 3Y27.11%
EPS Next 5Y36.17%
Revenue 1Y (TTM)6.18%
Revenue growth 3Y5.2%
Revenue growth 5Y-2.59%
Sales Q2Q%6.1%
Revenue Next Year52.71%
Revenue Next 2Y22.83%
Revenue Next 3Y27.17%
Revenue Next 5Y28.13%
EBIT growth 1Y-10.98%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y118.62%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y118.9%
OCF growth 3YN/A
OCF growth 5YN/A